PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...
With the changing lifestyle, young adults have put themselves in line for the risk of heart diseases. The new risk calculator’s predictions raise concerns.
The most dangerous heart attack risk this holiday travel season isn’t cholesterol, it’s inflammation
Millions of Americans will board planes and travel long distances this holiday season, many of them living with known heart ...
Cholesteryl ester transfer protein inhibition has previously demonstrated significant efficacy in reducing atherogenic lipids and may benefit high-risk patients who are unable to achieve their LDL ...
Released in 2023, PREVENT is a tool estimating CVD, ASCVD, and heart failure risk over 10 or 30 years for adults as young as ...
Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...
Statin therapy may attenuate the elevated MACE risk typically observed with tofacitinib vs TNF inhibitors among patients with RA and pre-existing ASCVD.
Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we ...
NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode the predictive genetics company focused on the prevention of cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback